Regeneron To Buy Assets Of 23andMe For $256M: Retail Says ‘Fantastic’ For Future R&D Efforts

Drugmaker Regeneron Pharmaceuticals, Inc. (REGN) said on Monday that it will acquire the assets of bankrupt biotechnology company 23andMe Holding Co. for $256 million.

Regeneron intends to acquire 23andMe’s Personal Genome Service (PGS), Total Health, and Research Services business lines, together with its Biobank and associated assets. The purchase, however, does not include the bankrupt company’s telehealth service, Lemonaid Health.

The agreement follows Regeneron’s successful bid in the bankruptcy auction for 23andMe’s assets. The DNA testing firm filed for bankruptcy in March 2025.

23andMe will operate as a wholly owned direct or indirect unit of Regeneron and continue operations as a personal genomics service upon closing the deal. The company said additional details on future operations will be shared during the deal closing.

The transaction is expected to close in the third quarter of 2025, subject to approvals by the bankruptcy court and regulator, and other customary closing conditions.

The asset purchase will help Regeneron strengthen its position in genetics-guided research and drug development to help people with serious diseases, it said. 

The company added that it intends to ensure compliance with 23andMe’s consumer privacy policies and applicable laws regarding the treatment of customer data. It also expressed willingness to detail the intended use of customer data and the privacy programs and security controls in place for review by a court-appointed, independent Customer Privacy Ombudsman.

On Stocktwits, retail sentiment about Regeneron stayed within the ‘bearish’ territory over the past 24 hours while message volume fell from ‘normal’ to ‘low’ levels.

A Stocktwits user expressed optimism, saying the deal would be ‘fantastic for their future R&D efforts.’

REGN stock has declined about 17% this year and about 40% over the past 12 months.

Also See: CrowdStrike Teams Up With Nvidia To Shield AI Factories: Retail Sentiment Improves

For updates and corrections, email newsroom[at]stocktwits[dot]com.